Baker McKenzie acted as the Hong Kong and US legal adviser to the joint sponsors and underwriters in connection with the global offering and listing of Mirxes Holding Company Limited (“Mirxes”) on the Main Board of the Hong Kong Stock Exchange. The company’s shares (stock code: 2629) commence trading today.
Mirxes, headquartered in Singapore, is a micro ribonucleic acid (miRNA) technology company specializing in providing effective, non-invasive and affordable blood-based miRNA test kits for the early screening of cancer and other diseases. Mirxes is one of the few companies globally that have obtained regulatory approval for in vitro diagnostic (IVD) products in the molecular cancer screening industry. It is also the world’s first and only company to obtain regulatory approval for IVD products used in molecular gastric cancer screening.
The deal team, comprising lawyers from Baker McKenzie and FenXun, was led by Baker McKenzie Partners Dan Ouyang and Winfield Lau. Other team members included Ke (Ronnie) Li and Zhenzhen Bao from FenXun, as well as Senior Associate Haoqian Chen and Associate Celia Li from Baker McKenzie. FenXun is Baker McKenzie’s joint operation platform partner in China.
Commenting on the transaction, Dan Ouyang, who co-chairs Baker McKenzie’s Capital Markets Practice in Asia Pacific and China, said: “We are delighted to have supported the joint sponsors and underwriters in this significant IPO. We are eager to continue leveraging our robust capital markets expertise to assist our clients with their future transactions as Hong Kong’s capital market activities gain momentum.”
China International Capital Corporation Hong Kong Securities Limited and CCB International Capital Limited acted as joint sponsors and joint sponsor-overall coordinators in this deal. They also acted as joint overall coordinators, joint global coordinators, joint bookrunners and joint lead managers, along with CMBC Securities Company Limited.
Baker McKenzie is one of the leading firms for complex transactions, providing strategic advice on deals involving the world’s leading financial institutions and multinational companies. The Firm regularly advises target companies, offerors, selling shareholders and financial advisers on the acquisition and disposal of companies listed on stock exchanges in key major financial centers, as well as issuers on their proposed listing and fund-raising activities in different jurisdictions. With many of its lawyers enjoying established working relationships with local regulators in Hong Kong and other key markets, the Firm is able to guide clients through all stages of the process. This includes providing valuable insights on regulatory developments that could impact the value and feasibility of cross-border transactions, as well as on ongoing compliance issues. The team also assists listed companies in the restructuring of shareholdings, use of stock as consideration, and block trades. Moreover, the team has extensive experience in advising clients on cross-border capital fund raising under different schemes, including the Shanghai-London Stock Connect and the China-Switzerland Stock Connect.
